Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018

  • ID: 4482745
  • Drug Pipelines
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Icon Bioscience Inc
  • Ohr Pharmaceutical Inc
  • PanOptica Inc
  • Ribomic Inc
  • MORE
Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape.

Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively.

Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Icon Bioscience Inc
  • Ohr Pharmaceutical Inc
  • PanOptica Inc
  • Ribomic Inc
  • MORE
Introduction

Report Coverage

Proliferative Diabetic Retinopathy (PDR) - Overview

Proliferative Diabetic Retinopathy (PDR) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Proliferative Diabetic Retinopathy (PDR) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development

Acucela Inc

Aerie Pharmaceuticals Inc

Antisense Therapeutics Ltd

Icon Bioscience Inc

Ohr Pharmaceutical Inc

PanOptica Inc

Ribomic Inc

ThromboGenics NV

Proliferative Diabetic Retinopathy (PDR) - Drug Profiles

AR-13503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atesidorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cyclosporine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emixustat hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAN-90806 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

squalamine lactate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-687 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects

Proliferative Diabetic Retinopathy (PDR) - Product Development Milestones

Featured News & Press Releases

Oct 14, 2016: PanOptica Reports Positive Results from Phase 1/2 Clinical Trial of PAN-90806, a Novel Topical Anti-VEGF Eye Drop

May 08, 2016: Acucela Initiates Phase 2 Clinical Trial Addressing Proliferative Diabetic Retinopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Acucela Inc, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Aerie Pharmaceuticals Inc, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Antisense Therapeutics Ltd, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Icon Bioscience Inc, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ohr Pharmaceutical Inc, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by PanOptica Inc, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by Ribomic Inc, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Pipeline by ThromboGenics NV, H1 2018

Proliferative Diabetic Retinopathy (PDR) - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Proliferative Diabetic Retinopathy (PDR), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acucela Inc
  • Aerie Pharmaceuticals Inc
  • Antisense Therapeutics Ltd
  • Icon Bioscience Inc
  • Ohr Pharmaceutical Inc
  • PanOptica Inc
  • Ribomic Inc
  • ThromboGenics NV
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll